Circulating Irisin Levels and Redox Status Markers in Patients with Gastric Cancer: A Case-Control Study

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Irisin, a myokine primarily known for exercise-induced fat browning, has been detected in cancer cells.
• Its potential as a biomarker for early cancer diagnosis, particularly Gastric Cancer (GC), is under investigation.

Purpose of the Study:

• To compare serum irisin levels between GC patients and healthy controls.
• To investigate the relationship between serum irisin and oxidative stress markers in GC.

Main Methods:

• A case-control study involving 22 newly diagnosed GC patients and 29 healthy controls.
• Serum irisin levels were quantified using ELISA.
• Oxidative stress markers (total antioxidant power, thiol group, malondialdehyde, superoxide dismutase) were measured.

Main Results:

• Serum irisin levels were significantly elevated in GC patients compared to healthy controls (p=0.032).
• No significant differences were found in total antioxidant power, malondialdehyde, thiol groups, or superoxide dismutase between the groups.
• No significant association was observed between irisin and the measured oxidative stress markers.

Conclusions:

• Elevated serum irisin levels in GC patients indicate its potential role in early GC diagnosis.
• Irisin may be a promising novel diagnostic indicator for gastric cancer.